Advertisement
Advertisement


News

NIH's Dr. Carl Dieffenbach Discusses HIV Treatment Science at 2016 Ryan White Conference

August 26, 2016

As the 2016 National Ryan White Conference on HIV Care and Treatment wound down in Washington, D.C., NIH's Dr. Carl Dieffenbach and his colleague Anne Rancourt joined us for a conversation on Facebook Live about HIV treatment. They discussed what scientists now know about the benefits of HIV treatment and when people diagnosed with HIV should begin treatment.

Dr. Dieffenbach and Ms. Rancourt also discussed how the Ryan White HIV/AIDS Program as well as some jurisdictions are making big strides in improving outcomes along the HIV care continuum, increasing the proportion of individuals living with HIV who are in care, on treatment, and with a suppressed viral load. They also highlighted some ongoing NIH-supported research on HIV treatment. These include studies aimed at developing long-acting formulations of antiretroviral therapy (ART). In addition, NIH is supporting studies that address comorbidities that people living with HIV are experiencing as they live longer lives because of effective HIV treatment. One example is the REPREIVE Trial, which is studying how to prevent heart disease among people living with HIV.

View their conversation here. You can also view other videos and more coverage from the 2016 Ryan White Conference on AIDS.gov's Facebook page.



Related Stories

2016 National Ryan White Conference on HIV Care and Treatment: Day Three Recap
2016 National Ryan White Conference on HIV Care and Treatment: Day Two Recap
2016 National Ryan White Conference on HIV Care and Treatment: Day One Recap



This article was provided by HIV.gov.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.